Aripiprazole: pharmacology and evidence in bipolar disorder

Bibliography

• MCINTYRE RS, KONARSKI JZ: Bipolar disorder: a national health concern. CNS Spectr. (2004) 9(11 Suppl. 12):6-15.
   Google Scholar
• PEELE PB, XU Y, KUPFER DJ: Insurance expenditures on bipolar disorder: clinical and parity implications. Am. J. Psychiatry (2003) 160(7):1286-1290.
   PubMed Web of Science ®Google Scholar
• YATHAM LN, KENNEDY SH, O’DONOVAN C et al.: Canadian Network for Mood and Anxiety Treatments (CANMAT) guidelines for the management of patients with bipolar disorder: consensus and controversies. Bipolar Disord. (2005) 7(Suppl. 3):5-69.
   PubMed Web of Science ®Google Scholar
• MCINTYRE RS, KONARSKI JZ: Tolerability profiles of atypical antipsychotics in the treatment of bipolar disorder. J. Clin. Psychiatry (2005) 66(Suppl. 3):28-36.
   PubMed Web of Science ®Google Scholar
• KINGHORN WA, MCEVOY JP: Aripiprazole: pharmacology, efficacy, safety and tolerability. Expert Rev. Neurother. (2005) 5(3):297-307.
   Google Scholar
• BRISTOL-MYERS SQUIBB COMPANY, OTSUKA AMERICA PHARMACEUTICAL INC.: Aripirazole Product Monograph. Product Monograph. 1-10-2006.
   Google Scholar
• DELEON A, PATEL NC, CRISMON ML: Aripiprazole: a comprehensive review of its pharmacology, clinical efficacy, and tolerability. Clin. Ther. (2004) 26(5):649-666.
   PubMed Web of Science ®Google Scholar
• STAHL SM: Dopamine system stabilizers, aripiprazole, and the next generation of antipsychotics, part 2: illustrating their mechanism of action. J. Clin. Psychiatry (2001) 62(12):923-924.
   PubMed Web of Science ®Google Scholar
• BOWLES TM, LEVIN GM: Aripiprazole: a new atypical antipsychotic drug. Ann. Pharmacother. (2003) 37(5):687-694.
   PubMed Web of Science ®Google Scholar
• WOOD MD, SCOTT C, CLARKE K et al.: Aripiprazole and its human metabolite are partial agonists at the human dopamine D2 receptor, but the rodent metabolite displays antagonist properties. Eur. J. Pharmacol. (2006) 546(1-3):88-94.
   PubMed Web of Science ®Google Scholar
• AIHARA K, SHIMADA J, MIWA T et al.: The novel antipsychotic aripiprazole is a partial agonist at short and long isoforms of D2 receptors linked to the regulation of adenylyl cyclase activity and prolactin release. Brain Res. (2004) 1003(1-2):9-17.
   PubMed Web of Science ®Google Scholar
• TADORI Y, MIWA T, TOTTORI K et al.: Aripiprazole’s low intrinsic activities at human dopamine D2L and D2S receptors render it a unique antipsychotic. Eur. J. Pharmacol. (2005) 515(1-3):10-19.
   PubMed Web of Science ®Google Scholar
• KECK PE Jr, CALABRESE JR, MCQUADE RD et al.: A randomized, double-blind, placebo-controlled 26-week trial of aripiprazole in recently manic patients with bipolar I disorder. J. Clin. Psychiatry (2006) 67(4):626-637.
   PubMed Web of Science ®Google Scholar
• CHESSICK CA, ALLEN MH, THASE M et al.: Azapirones for generalized anxiety disorder. Cochrane Database Syst. Rev. (2006) 3:CD006115.
   Google Scholar
• KECK PE Jr, MARCUS R, TOURKODIMITRIS S et al.: A placebo-controlled, double-blind study of the efficacy and safety of aripiprazole in patients with acute bipolar mania. Am. J. Psychiatry (2003) 160(9):1651-1658.
   PubMed Web of Science ®Google Scholar
• SACHS G, SANCHEZ R, MARCUS R et al.: Aripiprazole in the treatment of acute manic or mixed episodes in patients with bipolar I disorder: a 3-week placebo-controlled study. J. Psychopharmacol. (2006) 20(4):536-546.
   PubMed Web of Science ®Google Scholar
• VIETA E, BOURIN M, SANCHEZ R et al.: Effectiveness of aripiprazole v. haloperidol in acute bipolar mania: double-blind, randomised, comparative 12-week trial. Br. J. Psychiatry (2005) 187:235-242.
   PubMed Web of Science ®Google Scholar
• SUPPES T, DENNEHY EB, HIRSCHFELD RM et al.: The Texas implementation of medication algorithms: update to the algorithms for treatment of bipolar I disorder. J. Clin. Psychiatry (2005) 66(7):870-886.
   PubMed Web of Science ®Google Scholar
• TOHEN M, CALABRESE JR, SACHS GS et al.: Randomized, placebo-controlled trial of olanzapine as maintenance therapy in patients with bipolar I disorder responding to acute treatment with olanzapine. Am. J. Psychiatry (2006) 163(2):247-256.
   PubMed Web of Science ®Google Scholar
• CALABRESE JR, BOWDEN CL, SACHS G et al.: A placebo-controlled 18-month trial of lamotrigine and lithium maintenance treatment in recently depressed patients with bipolar I disorder. J. Clin. Psychiatry (2003) 64(9):1013-1024.
   PubMed Web of Science ®Google Scholar
• BOWDEN CL, CALABRESE JR, SACHS G et al.: A placebo-controlled 18-month trial of lamotrigine and lithium maintenance treatment in recently manic or hypomanic patients with bipolar I disorder. Arch. Gen. Psychiatry (2003) 60(4):392-400.
   PubMed Web of Science ®Google Scholar
• BOWDEN CL, CALABRESE JR, WALLIN BA et al.: Illness characteristics of patients in clinical drug studies of mania. Psychopharmacol. Bull. (1995) 31(1):103-109.
   PubMedGoogle Scholar
• ZARATE CA Jr, TOHEN M: Double-blind comparison of the continued use of antipsychotic treatment versus its discontinuation in remitted manic patients. Am. J. Psychiatry (2004) 161(1):169-171.
   PubMed Web of Science ®Google Scholar
• MCINTYRE RS, KONARSKI JZ, KECK PE: Psychotropic-induced weight gain: liability, mechanisms and treatment approaches. In: Obesity and Mental Disorders. Taylor and Francis, Oxford (2005):307-352.
   Google Scholar
• MCINTYRE RS, KONARSKI JZ, SOCZYNSKA JK et al.: Medical comorbidity in bipolar disorder: implications for functional outcomes and health service utilization. Psychiatr. Serv. (2006) 57(8):1140-1144.
   PubMed Web of Science ®Google Scholar
• OSBY U, BRANDT L, CORREIA N et al.: Excess mortality in bipolar and unipolar disorder in Sweden. Arch. Gen. Psychiatry (2001) 58(9):844-850.
   PubMed Web of Science ®Google Scholar